Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. Also provided herein are pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
Claims18
A kit, comprising:
- a) a pharmaceutical composition comprising,
- (i) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding a transgene, and
- (ii) a pharmaceutically acceptable carrier;
- and
- b) a package insert comprising instructions for administering the pharmaceutical composition,
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP4 herpes simplex virus gene,
- wherein the pharmaceutical composition is topically or transdermally administered to a subject,
- wherein the pharmaceutical composition is administered to one or more areas of the subject affected by a wound, disorder, or disease of the skin,
- wherein the pharmaceutically acceptable carrier comprises glycerol, and
- wherein the one or more polynucleotides encoding the transgene does not comprise a miRNA binding site.
A kit, comprising:
- a) a pharmaceutical composition comprising,
- (i) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding a transgene, and
- (ii) a pharmaceutically acceptable carrier;
- and
- b) a package insert comprising instructions for administering the pharmaceutical composition,
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP4 herpes simplex virus gene,
- wherein the pharmaceutical composition comprises an ointment, paste, cream, suspension, emulsion, fatty ointment, gel, powder, lotion, solution, spray, patch, or microneedle array,
- wherein the pharmaceutical composition is administered to one or more areas of a subject affected by a wound, disorder, or disease of the skin,
- wherein the pharmaceutically acceptable carrier comprises glycerol, and
- wherein the one or more polynucleotides encoding the transgene does not comprise a miRNA binding site.
Dependencies are inferred from the claim text.